Want to see OSUR full AI Analyst Report?
OSUR Stock Chart & Stats
$3.71
$0.00(0.00%)
At close: 4:00 PM EDT
$3.71
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$2.08 - $4.58
Previous CloseN/A
Volume125.75K
Average Volume (3M)426.50K
Market Cap
$248.98M
Enterprise Value$169.65
Total Cash (Recent Filing)$160.58M
Total Debt (Recent Filing)$12.09M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Nov 10, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.69
Shares Outstanding68,968,630
10 Day Avg. Volume386,941
30 Day Avg. Volume426,496
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.52
Price to Sales (P/S)1.55
P/FCF Ratio-3.34K
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.05
Revenue Forecast (FY)$120.50M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Zero DebtA substantial cash balance with no debt gives OraSure flexibility to fund Colli-Pee and Ebola 2.0 launches, absorb operating volatility, and continue product development without immediate financing pressure.
Regulatory Milestones Expand Product ReachClearance for at-home STI sample collection and Ebola 2.0 authorization broaden OraSure’s accessible diagnostics portfolio, support public-health relevance, and create potential for durable adoption through clinical and institutional channels.
Sequential Recovery And Margin ImprovementImproving revenue across Diagnostics and SMS, combined with higher gross margins from lower scrap and operational efficiencies, suggests stabilization efforts are gaining traction and could support the reiterated 2026 growth outlook.
Bears Say
Severe Revenue And Profitability DeteriorationThe sharp contraction in revenue and deeply negative operating results indicate that OraSure’s cost base is not yet aligned with demand. Persistent losses could limit reinvestment capacity and weaken the durability of its recovery.
Sustained Cash BurnCurrent cash consumption remains a material fundamental risk despite strong liquidity. If operating losses and working-capital pressure persist, the company may need to reduce investment or eventually seek external capital.
IntelliQ Regulatory SetbackThe delayed IntelliQ pathway removes a potentially important near-term growth catalyst and leaves resubmission timing uncertain. This increases reliance on Colli-Pee, Ebola 2.0, and existing products to drive the planned recovery.
Orasure Technologies News
OSUR FAQ
What was Orasure Technologies’s price range in the past 12 months?
Orasure Technologies lowest stock price was $2.08 and its highest was $4.58 in the past 12 months.
What is Orasure Technologies’s market cap?
Orasure Technologies’s market cap is $248.98M.
When is Orasure Technologies’s upcoming earnings report date?
Orasure Technologies’s upcoming earnings report date is Nov 10, 2026 which is in 67 days.
How were Orasure Technologies’s earnings last quarter?
Orasure Technologies released its earnings results on Aug 05, 2026. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.36.
Is Orasure Technologies overvalued?
According to Wall Street analysts Orasure Technologies’s price is currently Overvalued.
Does Orasure Technologies pay dividends?
Orasure Technologies does not currently pay dividends.
What is Orasure Technologies’s EPS estimate?
Orasure Technologies’s EPS estimate is -0.23.
How many shares outstanding does Orasure Technologies have?
Orasure Technologies has 68,968,630 shares outstanding.
What happened to Orasure Technologies’s price movement after its last earnings report?
Orasure Technologies reported an EPS of $0.09 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went down -3.614%.
Which hedge fund is a major shareholder of Orasure Technologies?
Currently, no hedge funds are holding shares in OSUR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orasure Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Neutral
OSUR Sentiment 100%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Orasure Technologies
OraSure Technologies, Inc. and its affiliates are a global leader in the development, production, and commercialization of advanced oral fluid diagnostic solutions and specialized specimen collection tools, serving markets across the United States, Europe, and other international regions. The company operates through two primary divisions: Diagnostics and Molecular Solutions. Its diverse Diagnostics portfolio features a range of crucial offerings, such as the InteliSwab rapid tests for COVID-19 (including professional and prescription versions). It also provides several OraQuick rapid tests, encompassing solutions for HIV (Rapid, In-Home, and Self-Test versions), Hepatitis C (HCV rapid antibody), and Ebola (rapid antigen). Further diagnostic tools include the OraSure oral fluid collection device, utilized for HIV-1 antibody screening and confirmation; the Intercept drug testing systems; various immunoassay tests and reagents; and the Q.E.D. saliva alcohol test. Within its Molecular Solutions segment, OraSure offers an array of genomic products, notably under the Oragene and ORAcollect brand names, alongside specialized microbiome collection solutions and comprehensive GenoFIND genomics laboratory services. The company also supplies collection devices like ORAcollect, RNA, OMNIgene, and RAL, specifically designed for COVID-19 molecular testing. Another key offering is the Colli-Pee device, engineered for the precise volumetric collection of first-void urine. Furthermore, OraSure produces and distributes advanced kits for the collection, stabilization, transportation, and storage of genetic material samples, critical for molecular testing in diverse fields such as academic research, commercial applications (including ancestry, disease risk management, lifestyle analysis), and animal testing. Complementing these, it also provides various other diagnostic tools, including immunoassays and in vitro diagnostic tests. OraSure's sophisticated products and services are distributed to a wide array of clients, including clinical laboratories, hospitals, clinics, various community and public health organizations, wholesale distributors, governmental bodies, medical practices, and a broad spectrum of commercial and industrial entities. Established in 2000, OraSure Technologies, Inc. maintains its corporate headquarters in Bethlehem, Pennsylvania.
OSUR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.View all OSUR earnings summariesTechnical Analysis
InfuSystem Holdings
―
Stereotaxis
―
Utah Medical Products
―
Microbot Medical
―
Sanara MedTech
―
Ownership Overview
5.62% Insiders
16.48% Mutual Funds
28.61% Other Institutional Investors
36.81% Public Companies and
Individual Investors







